Risk of travel-related cases of Zika virus infection is predicted by transmission intensity in outbreak-affected countries by unknown
Ogden et al. Parasites & Vectors  (2017) 10:41 
DOI 10.1186/s13071-017-1977-zRESEARCH Open AccessRisk of travel-related cases of Zika virus
infection is predicted by transmission
intensity in outbreak-affected countries
Nicholas H. Ogden1*, Aamir Fazil2, David Safronetz3, Michael A. Drebot3, Justine Wallace2, Erin E. Rees1,
Kristina Decock3 and Victoria Ng2Abstract
Background: Zika virus (ZIKV) infection is emerging globally, currently causing outbreaks in the Caribbean, and
Central and South America, and putting travellers to affected countries at risk. Model-based estimates for the basic
reproduction number (R0) of ZIKV in affected Caribbean and Central and South American countries, obtained from
2015 to 2016 human case surveillance data, were compared by logistic regression and Receiver-Operating
Characteristic (ROC), with the prevalence of ZIKV-positive test results in Canadians who travelled to them.
Results: Estimates of R0 for each country were a good predictor of the ZIKV test result (ROC area under the curve = 0.83)
and the odds of testing positive was 11-fold greater for travellers visiting countries with estimated R0≥ 2.76, compared to
those visiting countries with R0 < 2.76.
Conclusions: Risk to travellers varies widely amongst countries affected by ZIKV outbreaks. Estimates of R0
from surveillance data can assist in assessing levels of risk for travellers and may help improve travel advice.
They may also allow better prediction of spread of ZIKV from affected countries by travellers.
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Zika virus (ZIKV) infection is a globally emerging infec-
tious disease that is, at the time of writing, particularly af-
fecting countries in the Caribbean, and Central and South
America [1]. Outcomes of ZIKV infection are mild in
most cases but in recent outbreaks more severe outcomes,
including Guillain-Barré syndrome (GBS) and foetal cen-
tral nervous system developmental abnormalities (particu-
larly microcephaly), are now recognised [2]. It is thought
that ZIKV is primarily transmitted in tropical and sub-
tropical regions by the mosquitoes Aedes aegypti and Ae.
albopictus [3, 4], but sexual transmission also occurs in
humans [5–8]. However, to date epidemic/endemic trans-
mission of ZIKV has been limited to tropical and subtrop-
ical regions (according to data in [4]). This suggests that
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their own in the absence of tropical/subtropical Aedes
spp. vectors [4, 9] and/or a climate warm enough for
ZIKV transmission by these species [4, 10].
To manage risks for residents of ZIKV-free countries
there are two key questions: (i) How does risk for travel-
ling citizens vary from one affected country to another?
This is a function of environmental factors (e.g. climate,
habitat, altitude) and socioeconomic factors (e.g. popula-
tion density, the built environment and the capacity for
countries to control infection) that determine the
location-specific efficiency of virus transmission cycles
and thus the abundance of human-biting infective vectors
[11–13]. (ii) From which affected countries are returning
travellers most likely to come with ZIKV viraemia and
possibly capable of seeding endemic transmission? This
also depends on the abundance of human-biting infective
vectors, but also on the total numbers of travellers and the
proportions that use air travel, the speed of which allows
infected individuals to travel long distances while stillle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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simply correlate with the force of infection in affected
countries. However, many travellers may go to holiday re-
sorts or other locations where the risk of infection is dra-
matically different from that of the resident populations.
The intrinsic location-specific efficiency of mosquito-
borne virus transmission cycles determines the level of
risk of Zika virus infection to which travellers are ex-
posed, and during the initial phase of an outbreak this
risk of infection is positively associated with the basic
reproduction number (R0) of Zika virus in the affected
country. R0 is the number of new cases of disease in
humans produced by one case in a naïve population
under the conditions of the particular location under
study, and is the gold-standard metric of the capacity of
an infectious agent to propagate [15].
In this study we assess the relationship between the pro-
portions of Canadian travellers that test positive for ZIKV
after travelling to countries where ZIKV is or has recently
been epidemic, and estimates for R0 in those countries ob-
tained from human case surveillance data. We find evi-
dence that these are related, suggesting that estimation of
transmission efficiency in affected countries may be used
to nuance assessments of risk for travellers, and allow
more precise estimates of the rates of introduction and
spread of ZIKV by ZIKV-viraemic travellers.
Methods
Zika surveillance data
Data for 39 countries and territories of the Caribbean, and
Central and South America with confirmed autochthonous
transmission of ZIKV were obtained from the Pan
American Health Organization [16]. Data extracted on June
16, 2016 contained 377,525 ZIKV cases (364,030 suspected
and 13,495 confirmed cases) reported between August 15,
2015 and June 11, 2016. Case counts were reported by epi-
demiological week with a date corresponding to the first
day of that week. PAHO provides recommendations for
case definitions of confirmed and suspected cases [17];
however, case definitions vary amongst countries and these
are detailed in Additional file 1. For this study, confirmed
and suspected cases were combined for each country due
to the varying case definitions and degree to which
confirmed and suspected cases are reported.
Estimation of the basic reproduction number (R0)
The Incidence Decay and Exponential Adjustment (IDEA)
model was used to estimate R0 for each ZIKV affected
country. The IDEA model is a one equation, mathematical
model that can be used to describe epidemic dynamics
when only basic epidemiological information is available
[18]. The basis of the IDEA model is that in the absence of
intervention or population immunity, the number of cases
will grow exponentially with each serial interval (t; the timeit takes for infection in one person to give rise to infection
in another person via transmission by a mosquito) by a
factor that is R0. In reality, epidemics decay within a time-
frame due to processes such as increases in population im-
munity and/or control efforts of one form or another. The
IDEA model accounts for this decay by estimating a “con-
trol factor”, d which represents all dynamic processes that
slow epidemic growth (e.g. public health interventions, de-
clining vector abundance, and increasing herd immunity).
The IDEA model form is:
It ¼ R0= 1þ dð Þt
 t
where It is the number of new cases in a serial interval t,
R0 is the basic reproduction number, and d is the control
factor [18].
Using this equation, estimates for R0 and d were calcu-
lated from the changes in case counts observed over suc-
cessive serial intervals in the ZIKV surveillance data during
the epidemic in each affected country. The optimization
tool, Solver, in Excel 2010 (Microsoft Corporation, Red-
mond, WA, US) was used for these estimations. The sum
of least squares approach was used to estimate the best fit
for R0 and d by minimizing the sum of the squared devia-
tions between the observed case counts and the predicted
case counts estimated by the model.
For these calculations, time zero of the epidemic in
each country was assumed to be the date of the first re-
ported confirmed or suspected ZIKV case. However, in
19 countries multiple cases were reported in the first
week of reporting. For these countries a burn-in period
was employed, which was the number of weeks prior to
the first week of reporting that the first case likely oc-
curred. This number of weeks was simply calculated as
the number of times the case counts in the first week of
reporting could be divided by two before a case count of
one was reached.
The IDEA model requires data input in the time scale
of the serial interval (t), so PAHO case data were trans-
formed from weekly case counts to corresponding serial
intervals. We selected a serial interval of 16 days based
on best estimates of 15 to 16 days with a possible range
of 10 to 23 days [19]. To rescale weekly PAHO data into
a 16-day serial interval, the PAHO data for each country
was linearly interpolated between weeks to obtain esti-
mates of daily case counts using Stata/IC for Windows
version 14.1 (College Station, TX, US). Then weekly case
count data were matched to each 16-day serial interval
(or other serial intervals for sensitivity analysis).
Testing of travellers
All ZIKV test data used in this study were obtained by test-
ing at the National Microbiology Laboratory (NML), Public
Health Agency of Canada. The diagnostic algorithms for
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by the Committee to Advise on Tropical Medicine and
Travel [20] and mostly agree with recommendations of the
United States Centers for Disease Control and Prevention
(CDC, [21]) and the World Health Organization [22]. Test-
ing for ZIKV was recommend for: (i) travellers returning to
Canada from areas with known or highly suspected ZIKV
transmission and who experienced symptoms consistent
with ZIKV infection; (ii) asymptomatic pregnant women
with travel history to affected regions; and (iii) those having
recent sexual contact with a partner who was confirmed to
be infected with ZIKV. As the latter type of exposure would
not be associated with travel, data on these tests were not
included in this study.
ZIKV testing was conducted using diagnostic assays de-
veloped and validated by CDC [23]. Acute sera collected
within 10–14 days post-onset from symptomatic individ-
uals were first tested for the presence of virus by RT-PCR
[23] with samples considered positive if both the gene tar-
gets in the PCR were positive. If negative, sera were tested
by an IgM-antigen capture enzyme-linked immunosorb-
ent assay (MAC-ELISA) and confirmed by plaque reduc-
tion neutralization test (PRNT) [23]. The PRNT assay was
conducted in parallel with a dengue virus PRNT assay and
only samples that yielded a 4-fold or higher titer for ZIKV
were considered positive.
The dataset used in this study comprised all ZIKV tests
performed at NML on individuals returning to Canada with
a travel history to a ZIKV affected country or territory up
to June 21, 2016. The de-nominated dataset included a case
ID, the date the test sample was received by NML and in-
formation on country/territory or countries/territories to
which the case had recently travelled (although precise
dates of travel were not available). A total of 5157 unique
test samples (of which 111 were positive) with a history of
travel were received between May 27, 2015 and June 17,
2016. However after eliminating samples that did not pre-
cisely identify countries or territories of travel, travel to po-
tentially Zika-affected countries or territories outside of the
Americas and those from travellers who visited multiple
Zika-affected countries or territories there were 4533 test
results available for the analysis.
Statistical analysis
The shape of the relationship between the likelihood of a
positive ZIKV test result and R0 values was investigated by
lowess smoothed estimation of the log of the odds ratio
for testing positive [24], to see if polynomial forms or cat-
egorisation of the explanatory variable were needed for
logistic regression analysis [25]. The relationship approxi-
mated to a step function so for analysis the data were cate-
gorised into two groups with high and low estimated R0
values. The performance of R0 values as a predictor of the
test result was assessed using the receiver operatingcharacteristic (ROC) area under the curve (AUC), and in
so doing, values for sensitivity and specificity of different
cut-off levels of R0 for predicting the test result were gen-
erated. ROC analysis provided a basis for selection of a R0
cut-off value to categorise the R0 values into one low
(value = 0) and one high (value = 1) group for logistic re-
gression analysis. The R0 cut-off value chosen was that
which gave the highest Youden index (= Specificity/100 +
Sensitivity/100 – 1, i.e. giving equal weight to specificity
and sensitivity [26]). To quantify the difference in the like-
lihood of travellers testing positive after visiting countries
with high versus low R0 values, logistic regression was run
using ZIKV test result as the outcome and the dichoto-
mised R0 value groups as the explanatory variable. To ac-
count for unmeasured sources of variation amongst
countries visited, an ID number for the country visited by
the traveller was included as a random effect. Analyses
were undertaken using Stata/SE for Windows version 14.1
(College Station, TX, US) with the level of significance set
at P < 0.05. Data used in the analyses are available in
Additional file 2.
Sensitivity analysis
The only variable in the IDEA model that can affect esti-
mation of R0, and which can be varied by the user, is the
serial interval (t). We used a serial interval of 16 days for
the main analysis, however this figure is estimated from
limited data [19] and will likely vary with different envir-
onmental conditions including different seasons, mos-
quito biting rates and extrinsic incubation period
lengths. Therefore a sensitivity analysis was conducted
to assess how variations in the value of t may impact the
results of the study.
To do this, additional R0 estimates for each ZIVK-
affected country were estimated using the IDEA model
for one lower value for t (10 days) and one higher value
(23 days). The performance of the new R0 values as pre-
dictors of the test result was assessed as above using the
ROC AUC. The significance of differences in the AUC
values using R0 values obtained using the three different
values for t were assessed using the roccomp procedure
for testing the equality of two or more ROC areas [27]
in Stata/SE for Windows version 14.1. A cut-off level for
each of the two new R0 values, which gave the highest
Youden index values, was chosen to dichotomise the R0
values into low high groups as described above. Logistic
regression models (one for each set of R0 values obtained
with 10 and 23 day values for t) were then run using
ZIKV test result as the outcome and the dichotomised
R0 groups as explanatory variable with the ID number
for the country visited by the traveller included as a ran-
dom effect. All analyses were completed using Stata/SE
for Windows version 14.1 with the level of significance
set at P < 0.05.
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Zika surveillance and test result data
Of the 4533 Canadian traveller test results with informa-
tion on travel destination to a single country, 104 tested
positive and these travellers had visited one of 46 coun-
tries or territories in Central and South America. Of
these countries or territories there were 39 for which
ZIKV surveillance data were available. However data
from Belize, Cuba and Grenada were not used because
of very low case counts at the time of extraction. Data
from Brazil were also not used as they suggested that
surveillance began close to the peak of the epidemic and
back-interpolation to identify the approximate date of
the index case was considered unreliable. Furthermore,
surveillance for non-microcephaly cases ceased in early
2016 [28]. Data from Aruba, Paraguay and Peru were
not used because the ZIKV case data were sparse having
very few (2–3) weeks of reported cases that produced
very high (≥ 9) and likely spurious R0 values [18]. Data
from Puerto Rico were not used because case numbers
reported in the second and subsequent weeks of report-
ing (mean 428 per week) were stable and an order of
magnitude lower than the number of cases reported in
the first week (2705). These data also resulted in a very
high estimated R0 value, which we considered likely
spurious due to some anomaly in the reporting of cases
at the time of data extraction. Consequently, for analysis
there were data from 24 countries for which estimates of
R0 could be obtained, and for which there were ZIKV
test result data for Canadian travellers. The latter com-
prised 3551 test results, of which 92 (2.59%, exact 95%
confidence interval [95% CI] = 2.09–3.17%) were posi-
tive. The prevalence of positive test results amongst
countries varied from 0 to 33.3% (Fig. 1).Fig. 1 The prevalence (as a %) of ZIKV-positive test results (with exact 95% con
x-axis. Stars indicate the basic reproduction number (R0) estimates for each coun
US VI, US Virgin IslandsEstimation of R0
Case numbers predicted by the parameter estimates of
the IDEA model were in most cases consistent with ob-
served case numbers (Fig. 2). Estimates of R0 values ob-
tained for the 24 countries ranged from approaching
zero to 8.31 (Fig. 1). The prevalence of positive ZIKV
test results varied non-linearly with R0 estimates for the
countries (Fig. 3).
Receiver operating characteristic analysis
The ROC AUC value for estimates of R0 as predictors of
the ZIKV test result was good (AUC= 0.83, standard error
= 0.02, 95% CI = 0.79–0.87) according to accepted criteria
[26]. A cut-off value of ≥ 2.76 for R0 was chosen to dichot-
omise the ZIKV test data, which gave the greatest combined
specificity and sensitivity (73.6 and 84.6%, respectively).
Logistic regression analysis
In logistic regression with country ID included as a random
effect, travellers to countries with an estimated R0 ≥ 2.76
were 11 times more likely to test positive than travellers to
countries with an estimated R0 < 2.76 (odds ratio = 11.13;
95% CI = 3.14–39.25; Wald Z = 3.73, P < 0.001).
The proportions of travellers testing positive after
travelling to Zika-affected countries with an estimated
R0 ≥ 2.76 and < 2.76 were 11.2% (67/596) and 0.85% (25/
2955), respectively.
Sensitivity analysis
The R0 values obtained with 10 and 23 day values for t
were respectively lower and higher than the values ob-
tained using t = 16 days in most cases (Fig. 4). However,
for Saint Lucia and Curacao, R0 values obtained with 10
and/or 23 day values for t could not be obtained due tofidence intervals) in travellers visiting the ZIKV-affected countries on the
try. Abbreviations: DR, Dominican Republic; T and T, Trinidad and Tobago;
Fig. 2 Example surveillance data from ZIKV-affected countries. The bars show the reported numbers of cases (suspected and confirmed cases combined)
by 16 day serial interval period. The crosses show the predicted number of cases using the parameters obtained by the IDEA model [18]
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countries were not used in analyses.
ROC AUC values for the remaining data were the
same when t = 16 days and t = 23 days but slightly lower
when t = 10 days (Table 1). However there was no sig-
nificant difference between these AUC values (χ2 = 1.06,
P > 0.1). The optimal cut-off values for dichotomising
the R0 values were ≥ 1.93 when R0 values were obtained
with t = 10 days and ≥ 3.30 when R0 values were obtained
with t = 23 days. When using these cut-off values theFig. 3 The relationship of estimates of R0 for countries in Central and Sout
results for travellers to those countries. Crosses indicate prevalence values in
smoothed estimates of prevalence. The identified cut-off R0 value that dich
and there were 12 countries in each of these groupsproportions of positive test results in high and low R0
groups were the same when t = 23 days, but different
when t = 10 days (Table 2), which was reflected in the re-
sults of logistic regression (Table 3). When t was 23 days
the countries falling in the high and low risk groups
were the same as when t was 16 days. However when t
was 10 days, Colombia, the Dominican Republic and
Guatemala were classified as belonging to the high risk
group, while they were classified in the low risk group
when using t set at 16 and 23 days.h America and the Caribbean, to the prevalence of positive ZIKV test
travellers to an individual country and the dashed line is lowess
otomised countries into high-risk and low-risk for travellers was 2.76,
Fig. 4 The relationship between R0 estimated using t = 10 (circles) or t = 23 days (crosses), and R0 estimated using t = 16 days
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Estimates of R0 for ZIKV in outbreak-affected countries
correlated with the proportions of travellers acquiring
ZIKV. Therefore risk to travellers varies with the force
of transmission cycles in the countries they are visiting,
which suggests that travellers are not a group that is par-
ticularly highly protected from infection in affected
countries by virtue of their traveller status. This raises
the possibility that different levels of ZIKV infection risk
in different countries may be identified and possibly
communicated to travellers. The need for such nuanced
risk communication will become increasingly important
if ZIKV spreads more widely in the world, in which case
simply not visiting affected countries will become a de-
creasingly viable decision for many travellers. Second,
this study suggests that estimates of R0 (or other ana-
lyses of the force of infection) in affected countries could
be used to enhance methods used to assess the capacity
for ZIKV spread by travellers, which often account for
within-source country incidence using simple indices
[14, 29] or not at all [30]. Also, these estimates could
provide useful validation data for models predictingTable 1 Results of ROC analysis for R0 as a predictor of the ZIKV
test results, when R0 was estimated using t = 10, 16 and 23 days.
Note that data from Saint Lucia and Curacao were not available
for the sensitivity analysis
t-value used to estimate R0 ROC AUC SE 95% CI
10 days 0.77 1.27 0.79–0.87
16 days 0.79 2.34 0.74–0.84
23 days 0.79 2.34 0.74–0.83
Abbreviations: ROC AUC receiver-operating characteristic area under the curve,
SE standard error, CI confidence intervalimportation and spread of ZIKV that are being devel-
oped [31]. Such models predict actual numbers of cases
rather than the numbers reported in surveillance, which
vary amongst countries according to surveillance sys-
tems and effort, as well as according to the dynamics of
ZIKV transmission. The method we used here obtains
an estimate of R0 based on the shape of the epidemic
curve rather than the reported incidence so it allows
comparisons to be made amongst jurisdictions in which
surveillance effort may be different.
The relationship between estimated R0 for the ZIKV-
affected countries and infection prevalence in Canadian
travellers was nonlinear and we chose to use a simple R0
cut-off point to dichotomise the data for analysis. Why
this relationship was a step function is not clear. One
possible explanation is background noise within the re-
ported ZIKV case numbers, associated with false positiv-
ity and negativity, which may mask the real status of
transmission when incidence is low. More research and
data from more countries and time points during epi-
demics are needed to better understand the relationship
between R0 and incidence in travellers. Nevertheless, the
difference in incidence in travellers exposed to countries
above and below the identified R0 cut-off (2.76) was
stark. The likelihood of testing positive was an order of
magnitude greater in travellers to countries with R0
values at or above the cut-off compared to travellers to
countries with R0 values below the cut-off. The estimates
of R0 for each country provided an index of the status of
Zika transmission and risk of infection for travellers des-
pite variations amongst countries in surveillance effort
and case definition, and the fact that we are estimating
R0 mostly on the basis of symptomatic cases, when most
Table 2 The proportions of travellers positive in high and low risk countries determined using cut-off levels for R0 when R0 was
estimated using t = 10, 16 and 23 days. Note that data from Saint Lucia and Curacao were not used to estimate proportions when
R0 was estimated using t = 10 and 23 days
t-value used to estimate R0 Cut-off for R0 used
to determine high
and low risk countries
Proportion (%) positive
in ‘high risk’ group
Proportion (%) positive
in ‘low risk’ group
10 days 1.98 86/1480 (5.8) 5/2042 (0.2)
16 days 2.76 67/596 (11.2) 25/2955 (0.1)
23 days 3.30 67/596 (11.2) 24/2905 (0.1)
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the value of R0 = 2.76 may not be a hard and fast cut-off
figure, ready to use for developing risk communications.
It reflects the status of data we have to present at the
onset of the outbreak, both on Canadian travellers and
on surveillance in affected countries, and further study
will be needed to confirm its appropriateness for devel-
opment of sound risk communications.
We were not able to obtain an R0 value for Brazil for
the study period even though it is well recognised that
Brazil suffered a very significant epidemic. The preva-
lence of ZIKV-positive test results in Canadian travellers
(2%, 4/203 tests) was relatively low and more consistent
with Brazil being in the low risk group in our study. This
suggests that either Brazil was an outlier in terms of en-
vironmental risk for travellers equating with incidence of
infection, or that the epidemic was largely over by the
time many of the travellers visited Brazil. There is indeed
some evidence that the latter was the true. Phylogeny-
based estimates of the date of importation of ZIKV into
Brazil are as early as 2013 [32], while evidence from sur-
veillance for late-pregnancy microcephaly suggests that
the epidemic peaked early in 2015 [33].
The R0 estimates were sensitive to the value for the ser-
ial interval, but identification of high and low risk coun-
tries using R0 estimates was robust to variations in the
serial interval from 16 to 23 days. A serial interval of
10 days gave a qualitatively similar but quantitatively
somewhat different classification of the countries. Ten
days may, however, be biologically implausible as a mean
serial interval, so R0 values generated using this interval
could be expected to be less well predictive of the risk of
traveller infection than when using more plausible 16 or
23 day serial intervals. The serial interval comprises theTable 3 Parameter estimates from logistic regression models in
which the ZIKV test result was the outcome and risk group
(based on cut-off levels for R0 when R0 was estimated using
t = 10, 16 and 23 days) was the explanatory variable
R0 estimated using Odds ratio 95% CI Wald z P
t = 10 days 21.76 4.39–108.85 3.77 < 0.001
t = 16 days 11.13 3.12–39.25 3.73 < 0.001
t = 23 days 11.71 3.09–44.70 3.61 < 0.001
Abbreviation: CI confidence intervalintrinsic incubation period in humans (minimally 3 days
[19], but more likely 5 days and longer [34]), the extrinsic
incubation period in mosquitoes (as short as 5 days ex-
perimentally [35] but in nature more likely ≥ 10 days [36]),
the time mosquitoes take to feed twice, and considerations
of how the gonotrophic cycle in the mosquitoes affects
how frequently they feed [37]. Serial intervals have most
frequently been estimated at ≥ 14 days for related flavi-
viruses [38, 39] so it would perhaps be unsurprising if the
serial interval of ZIKV infections was similar.
There are other methods of estimating R0 or the effect-
ive reproduction number R from surveillance data (e.g.
[40, 41] and articles reviewed in [12]), but the IDEA model
approach was convenient because it provided an estimate
of R0 while accounting for factors (including control, sea-
sonal declines in vector numbers or herd immunity) that
contribute to post-epidemic peak declines in incidence.
Furthermore, it obtains estimates of R0 that allow compar-
isons to be made amongst jurisdictions in which surveil-
lance effort is different. However, as time goes on,
incidence will fall in affected countries for a range of rea-
sons (e.g. development of herd immunity and control ef-
forts), and ZIKV transmission will likely transition from
epidemic to endemic status. Once this occurs, methods
other than the IDEA model may be more appropriate for
assessing risk to travellers from surveillance data.
Conclusions
This study demonstrated that risk to travellers in ZIKV-
affected countries correlates with estimates of R0 for
those countries obtained using human case surveillance
data. This relationship was non-linear with risk of travel-
lers testing positive being over tenfold greater in coun-
tries with an estimated R0 equal to or greater than 2.76.
This suggests that estimates of the force of infection in
ZIKV-affected countries may be use to nuance risk in-
formation for travellers, and help predict rates of spread
of ZIKV from those countries.Additional files
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